Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June29

PSE S S S T

12222 Study of protease inhibitor combination in Europe (SPICE): saquinavir
soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected
individuals
Graeme Moyle, UK
12223 An open-label, randomized, comparative study of d4T+3TC+IDV versus
ZDV+3TC+IDV in treatment-naive HIV-infected patients (START I)
Roy Gulick*; K. Squires; W. Powderly;. Santana; J. Esinhart;
N. Schoellkopf; M. Stevens, USA
12224 Longterm comparison of BID and TID dosing Viracept (nelfinavir) in
combination with stavudine (d4T) and lamivudine (3TC) in HIV patients
Annakatrin Petersen*; Margaret Johnson, USA
12225 An open-label, randomized, comparative study of d4T + ddl + IDV versus
ZDV + 3TC + IDV in treatment-naive HIV-infected patients (START II)
Joseph Eron*; D. Peterson; R. Murphy; ]. Pottage; J. Mauney;
N. Schoellkoph; M. Stevens, USA
12226 Stavudine (d4T),didanosine (ddl),and nelfinavir combination therapy in
pretreated HIV-patients: Antiviral effect and safety in an ongoing study
Ulrich Hengge*; N.H. Brockmeyer; V. Exner; A. Beckman; M. Goos,
Germany
12227 ALBI (ANRS 070). A randomized controlled trial to evaluate the efficacy
and safety of AZT/3TC vs alternating d4T/ddl and AZT/3TC vs d4T/ddl
Jean-Michel Molina*; V. Journot; F. Ferchal; I. Pellegrin; C. Rancinan;
M.N. Sombardier; J.M. Decazes, France
12228 HIV viral load response in subjects switched from zidovudine (ZDV) -
containing to stavudine (D4T)-containing regimens in the Pacific Oaks
Population Study (POPS)
Mark Shaefer*; W.D. Hardy; L. Shaker-Irwin; V. Williams; C Maude;
J. Thommes; N. Graham; M. Shaefer, USA
12229 ADAM study: Induction-maintenance therapy in HIV-1 infection:
Early results
Monique M.E. Reijers*; GJ. Weverling; R. W. Ten Kate; P.M.J. Frissen;
F. De Wolf; M. Scmuitemaker; J.M.A. Lange, The Netherlands
12230 Safety and activity ofabacavir (1592, ABC) with 3TC/ZDV
in antiretroviral naive subjects
Margaret Fischl*; S. Greenberg; N. Clumeck; B. Peters; R. Rubio;
B. Pobiner; L. Verity, USA
12231 Retained effectiveness of protease inhibitor (PI) therapy (Rx)
following"protease sparing" nevirapine/nucleoside (NVP/nuc)
combination therapy
Robert Curry*; Patrick Robinson*; S.A. Hussain; M. W. Myers;
P.A. Robingson, USA
12232 Aggressive vs sequential therapy in experienced HIV pts:The Master Study
(Standardized Management of Antiretroviral Therapy)
Giampiero Carosi*; F. Castelli; G. Carnevale; F. Maggiolo; A.M. Orani;
M. Andreoni; G.M. Vigevani, Italy
12233 Lack of clinical or immunologic disease progression with transient use of
zidovudine (ZDV) to reduce perinatal HIV-1 transmission in PACTG 076
Arlene D. Bardeguez*; L.M. Mofenson; C. Spino; D.E. Shapiro;
M.G. Fowler; R. Sperling; R. Boyer, USA
12234 Immunologic and virologic markers as indicators of clinical outcome in
patients enrolled in the alpha ddl trial
Paul McQueen*; N.N. Zheng; S. Simasathiansophon; D.G. Smith;

M.G. Law; S.F Delaney; D.A. Cooper, Australia

12235 Hydroxyurea in combination regimens for the treatment of antiretroviral
naive, HIV-infected adults
Sergio Lupo; Marianne E. Federici; P Cahn; I. Cassetti; R. Pedro;
G. Ruiz-Palacios; J.S.G. Montaner; T. Kelleher, Argentina
12236 Retrospective analysis of protease inhibitor efficacy among patients
failing a Delavirdine regimen
Michael Para*; M. Weinstock, USA
12237 A multicenter randomised study comparing ritonavir and indinavir in
1251 previously treated patients with CD4 below 50/mm3.
(Italian ISS-IP1 Study Group)
Carlo Tomino*; Stefano Vella; F.V. Fragola; R.D. Ricciardulli;
S.A.C. Seeber; G.G. Giannini; P.M.F. Pirillo; F.M. Floridia, Italy
12238 An open randomized study comparing the influence of
different therapeutic strategies (no treatment vs double therapy
(ZDV/D4T+3TC) vs triple therapy (D4T+3TC+indinavir) in
the progression of chronic HIV-1 infected patients in very early stages
(Spanish Ea)
F. Garcia*;. Romeu; I. Grau; M.A. Sambeat; D. Dalmau; H. Knobel;
J.M. Gatell; J.M. Mirb, Spain
12239 Stavudine-didanosine-nevirapine: A convenient highly active triple
combination for first line antiretroviral therapy
Francois Raffi*; V. Reliquet; C. Francois; M. Garre; C. Hascoet;
C. Allavena; C. Arvieux, France
12240 Study HIV-NAT 001: A randomized double-blind, comparative trial
to evaluate the efficacy of combination antiviral therapy with
ZDV 200 mgTID plus ddC 0.75 mg TID versus ZDV 100 mg TID plus
ddC 0.375 mg TID for the treatment of HIV-1 infection in a Thai
Eugene Kroon*; M. Chuenyam; R. Van Leeuwen; W. Poolcharoen;
J. Lange; D. Cooper; P Phanuphak, Thailand
12241 Study HIV-NAT 002:The safety and efficacy of didanosine (ddl) +
stavudine (d4T) in high/low dose combinations in an antiretroviral
therapy naive Thai adult population with CD4 counts 150-350/mm3
and predominantly infected with HIV-1 clade E
Kiat Ruxrungtham*; C. Ungsedhapand; S. Teeratakulpisarn;
C. Kunanusont;. Lange; D. Cooper; P Phanuphak, Thailand
12242 Tolerability and toxicity of protease inibitor, containing regimens in
HIV-infected patients
Diego Ripamonti*; Alessandro Chiodera; P. Nasta; E. Bombana;
0. Oladati, Italy
NOTES

IUNE

CONFERENCE WORKBOOK

31